Novartis AG
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis Tafinlar + Mekinist (dabrafenib + trametinib by Year
Tafinlar + Mekinist (dabrafenib + trametinib — melanoma & BRAF-mutated cancers) ($M)
Novartis Tafinlar + Mekinist (dabrafenib + trametinib: $2,215M in FY2025, up 7.6% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Tafinlar + Mekinist | 2 215 | 2 058 | 8 | 6”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tafinlar + Mekinist (dabrafenib + trametinib — melanoma & BRAF-mutated cancers) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,215 | +7.6% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 2,058 | +7.1% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,922 | +8.6% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,770 | +4.5% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 1,693 | +9.8% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 1,542 | +15.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 1,338 | +15.8% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 1,155 | +32.3% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 873 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up tafinlar + Mekinist (dabrafenib + trametinib
Cite this data
StockData. (2026). Novartis Tafinlar + Mekinist (dabrafenib + trametinib ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-tafinlar-mekinist
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.